Q1 EPS Estimate for Aptevo Therapeutics Reduced by Analyst

Aptevo Therapeutics Inc. (NASDAQ:APVO) – Investment analysts at Roth Capital lowered their Q1 2025 earnings per share (EPS) estimates for Aptevo Therapeutics in a note issued to investors on Monday, February 17th. Roth Capital analyst J. Aschoff now expects that the biotechnology company will post earnings per share of ($4.21) for the quarter, down from their prior estimate of ($3.92). The consensus estimate for Aptevo Therapeutics’ current full-year earnings is ($14.81) per share. Roth Capital also issued estimates for Aptevo Therapeutics’ Q2 2025 earnings at ($4.16) EPS, Q3 2025 earnings at ($3.78) EPS, Q4 2025 earnings at ($3.74) EPS, FY2025 earnings at ($15.84) EPS, FY2026 earnings at ($14.49) EPS, FY2027 earnings at ($10.03) EPS and FY2028 earnings at ($3.57) EPS.

Separately, StockNews.com began coverage on Aptevo Therapeutics in a research note on Monday, December 9th. They issued a “sell” rating on the stock.

Aptevo Therapeutics Price Performance

Shares of APVO stock opened at $3.45 on Thursday. The business’s 50-day moving average price is $4.40 and its 200-day moving average price is $236.14. Aptevo Therapeutics has a 12 month low of $3.01 and a 12 month high of $399.60.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.